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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is associated with high mortality and will
become the second most common cause of cancer-associated mortality by 2030. The poor prognosis
arises from a lack of sensitive biomarkers, limited therapeutic options, and the astonishingly high
recurrence rate after surgery of 60–80%. The factors driving this recurrence, however, remain
enigmatic. Therefore, we generated patient-derived organoids (PDOs) from early- and late-recurrent
PDAC patients. Cellular identity of PDOs was confirmed by qPCR, ddPCR, and IHC analyses.
This is the first study investigating the metabolism in PDOs of different, clinically significant PDAC
entities by untargeted GC/MS profiling. Partial least square discriminant analysis unveiled global
alterations between the two sample groups. We identified nine metabolites to be increased in early
recurrent PDOs in comparison to late recurrent PDOs. More than four-times increased were fumarate,
malate, glutamate, aspartate, and glutamine. Hence, α-keto acids were elevated in PDO-conditioned
medium derived from early recurrent patients. We therefore speculate that an increased anaplerotic
metabolism fuels the Krebs-cycle and a corresponding higher accessibility to energy fastens the
recurrence in PDAC patients. Therein, a therapeutic intervention could delay PDAC recurrence and
prolong survival of affected patients or could serve as biomarker to predict recurrence in the future.
Keywords: pancreatic ductal adenocarcinoma; PDAC; recurrence; relapse; metabolomics; GC/MS;
patient derived organoids; PDO culture; anaplerotic TCA-cycle; glutamate
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common histological subtype of pancreatic
cancer and a highly aggressive and fast-growing type of cancer [1–3]. In about 90% to 95 % of
all pancreatic tumors, the cell-of-origin can be found in the pancreas ductal epithelium [1]. PDAC
is associated with a very poor prognosis [4], is one of the major causes for cancer-related death
in the western world [5] and is predicted to become the second-most cause of cancer-associated
mortality [6] by 2030 [7]. The 5-year survival rate of PDAC patients has changed only little during
recent years [5] and is now around 10% for all stages [8,9]. Important risk factors for PDAC include
genetic predisposition including germline mutations in BRCA2 [10], CDKN2A [11], and CFTR [12] as
well as smoking, diabetes, obesity and chronic pancreatitis [4,13]. The very low survival rates associated
with PDAC are due to several factors, of which the most important are the very rapid progression, early
microdissemination [14], and the late onset of any specific symptoms [15]. The majority of PDACs
are diagnosed at an advanced, locally irresectable or metastatic stage when only palliative therapies
can be offered [16]. Biologically, pancreatic cancers are locally highly infiltrative tumors with vascular
and perineural invasion being observed frequently. Moreover, locoregional lymphatic and/or distant
metastases are found at first diagnoses in the majority of cases [17]. The molecular pathology of PDAC
is extremely challenging with a 92–95% prevalence in non-druggable activating KRAS mutation next to
TP53 and/or CDKN2A alterations driving cancer survival, growth, resistance to therapeutic options
and metastasis [18]. These factors further contribute to a rapid progression of the disease [19] and
support anabolic metabolic pathways [15]. About 80% of all patients suffering from pancreatic cancer
have unresectable carcinoma at diagnosis, decreasing their estimated overall survival to only a few
months [20]. The therapeutic options for these patients are limited to combination chemotherapy,
which is associated with significant toxicity [15]. Many patients who undergo curative resection
experience disease recurrence within one year after surgery [21–24].
For patients initially presenting with surgically resectable PDAC (approximately 20%) [25], disease
recurrence after initial curative surgery is the major challenge and impediment to long-term survival.
Among all patients undergoing resection, cancer recurrence develops in up to 80% within time frames
of clinical trials and are probably even higher in real-life populations [26–28]. Many studies found
that the early post-operative recurrence is due to local and distant metastases [29]. Patients who
developed distant metastases early after surgery have only a limited median survival time of a few
months [30,31]. Studies trying to identify risk factors for recurrence after PDAC resection found tumor
size, carbohydrate antigen 19-9 (CA19-9), perineural invasion, and lymph node metastases to correlate
with disease recurrence [32–34]. However, it is likely that microscopic metastases have formed in the
majority of patients prior to surgery or radiation therapy [15]. However, the mechanisms determining
early or late PDAC recurrence after surgery have not yet been extensively studied [29–31] and better
predictive biomarkers are required for more successful clinical stratification of patients.
During the last decades, many attempts in pancreatic cancer research focused on understanding
molecular mechanisms within the tumor cells, the development of pancreatic cancer, and finding
new therapeutic options to overcome treatment resistance [35]. Moreover, different studies tried
to find novel biomarkers for the early detection of pancreatic cancer [36–38]. However, the use of
the limited number of established pancreatic cancer cell lines in these studies was associated with
several limitations. First, many cell lines were established from metastatic sites and do underrepresent
characteristics found in primary tumors or pancreatic intraepithelial neoplasia (PanIN) lesions [39],
and second, established cell lines grow extremely fast which could easily lead to the selection of different
clones and a genetic drift as reported previously [40]. Application of 3D-grown conventional cell
lines can in general overcome some issues of abnormal proliferation behavior observed in 2D-cultures
in comparison to in situ situations [41]. Other research systems include patient-derived xenografts
(PDX). However, these systems require large amounts of tissue [42] and need several months to be
established [43]. Genetically engineered mouse models of PDAC could give good insights into the
disease, but the systems are time-consuming, need a lot of space, and require high costs [44]. In order
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to overcome at least some of the limitations, 3D patient-derived pancreatic ductal organoids (PDO)
can be cultured directly from primary PDAC tissue, pancreatitis tissue, or even healthy pancreas [45].
Organoids are a cellular 3D system with self-renewal and self-organization capacity which maintains
an appearance and functionality comparable to their original tissue [39]. Moreover, the systems were
found to be genetically stable throughout many passages [46,47]. Human PDAC organoids could
generate PanIN lesions and develop into invasive PDAC after transplantation into mice [45]. With PDO
cultures, PDAC of a variety of patients can be modeled in vitro and experimental findings can be
correlated to the clinical course of the donating patients [45]. The organoid culture system allows
the expansion of primary tissue in an in vitro system which is much closer to the actual patient than
established cell lines are. Moreover, these systems allow the growth of 3D structures from healthy and
disease tissue making the direct comparison between both states more convenient [48]. One of the
major current limitations with organoid cultures from patient tissue is the limitation in cell expansion
and the heterogenic growth [48]. The cultures need relatively long to grow and to deliver sufficient cell
mass, compared to 2D cultures of established cell lines. Moreover, the organoid cultures depend on
many supplemental factors to grow in vitro [39].
In this study, we generated different PDOs from early and late recurrent PDAC patients. After the
evaluation of PDOs in regard to tissue-specificity, differences in primary metabolism between early
and late recurrence should be unveiled by untargeted GC/MS profiling. We found that PDOs derived
from early recurrent PDAC patients had higher levels of tricarboxylic acid intermediates and some
anaplerotic amino acids, suggesting a higher capacity to generate energy. Thus, early recurrence might
be the consequence of higher energy levels in these malignancies, suggesting a possible target to delay
recurrence in future PDAC therapy or potential biomarkers to predict recurrence.
2. Material and Methods
2.1. Preparation of Human Pancreas Organoid Feeding Medium
Feeding medium for human pancreas organoid cultures (PDO) was prepared freshly at least every
two weeks. The organoid splitting medium was prepared by supplementing Advanced DMEM/F-12
medium with 10 mM HEPES and 1× GlutaMAX™. The ROCK inhibitor Y-27632 (10.5 µM) was added
to the feeding medium directly before use. For organoid feeding medium, following ingredients
were added to the splitting medium (final concentrations are given): 100 µg/mL primocin, 500 nM
A38-01, 50 ng/mL mEGF, 100 ng/mL hFGF10, 10 nM gastrin I, 1.25 mM N-acetylcysteine, 10 mM
nicotinamide, 1× B27 supplement, 1× R-Spondin I-conditioned medium, 1× Wnt3a-conditioned
medium and 10.5 µM Y-27632.
2.2. Cultivation and Passaging of Human Pancreas Organoid Cultures
PDAC organoids were established [49] and cultured as described previously [45]. Organoids
were grown in 25 µL Matrigel Matrix Basement Membrane domes in 24-well plates. Cultures were
passaged once a week and split 1:2 if well-growing. Feeding medium was replaced twice a week.
For organoid passaging, matrigel domes were transferred into 10 mL cold splitting medium and kept
on ice until centrifugation. All centrifugation steps were performed at 1200 rpm and 4 ◦C for 5 min.
Organoids were centrifuged, splitting medium was discarded, cells were resuspended in 1 mL TrypLE
Express (RT), and incubated at 35 ◦C and 180 rpm for 15 min. Following, 9 mL of cold splitting medium
were added into each tube and cells were centrifuged again. Organoid cell pellets were subsequently
resuspended in cold Matrigel and immediately seeded into 24-well plates with 25 µL Matrigel for each
dome. Organoids were incubated at 37 ◦C for 15 min before 500 µL feeding medium were carefully
added into each well. Organoids were cultured at 37 ◦C and 5% CO2 in a humidified atmosphere.
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2.3. Isolation of Total RNA from Organoid Cultures
For isolation of RNA from organoid cultures, matrigel domes were resuspended in 1 mL ice-cold
1× PBS. The organoids were centrifuged at 5500 rpm and 4 ◦C for 6 min. The organoid pellets
were resuspended in 500 mL Cell Recovery Solution and incubated on ice for 60 min. Following,
the organoids were centrifuged (same settings as before) and washed once with 500 µL ice-cold 1× PBS.
The supernatant was discarded and the organoid pellets were immediately frozen at −80 ◦C. RNA
was isolated using the RNeasy® Plus Mini Kit (Qiagen, Hilden, Germany) and QIAshredder (Qiagen)
according to manufacturer’s instructions. Briefly, organoid pellets were resuspended in 350 µL Buffer
RLT Plus, loaded on a QIAshredder column and centrifuged at 13,000 rpm for 2 min. The homogenate
was transferred to a gDNA Eliminator spin column in a new collection tube and centrifuged for 30 s
at 10,000 rpm. A total volume of 525 µL 100% ethanol was added to the flow-through and shortly
vortexed. 700 µL of the mixture were loaded onto an RNeasy Mini spin column and centrifuged at
10,000 rpm for 30 s. The flow-through was discarded and the step was repeated until the whole sample
passed the membrane. Following, 500 µL Buffer RPE was added to the spin column and centrifuged at
10,000 rpm for 30 s. The flow-through was discarded and the step was repeated once. The mini spin
column was centrifuged at 13,000 rpm for 2 min to dry the membrane. The column was placed in a new
collection tube, 35 µL RNase-free water were added onto the membrane and columns were incubated
at RT for 3 min. Following, samples were centrifuged at 13,000 rpm for 2 min to elute total RNA.
2.4. Synthesis of cDNA from RNA Templates
The cDNA from RNA templates was synthesized using the RevertAid First Strand cDNA Synthesis
kit (Thermo Scientific, Waltham, MA, USA). Briefly, 1 µg total RNA was incubated with 0.5 µL OligodT
and 0.5 µg Random Hexamer primer for 5 min at 70 ◦C in a total volume of 12 µL. Following, 4 µL
Reaction Buffer (5×), 2 µL dNTP mix and 1 µL RNase inhibitor were added and the mix was incubated
for 5 min at 37 ◦C. After addition of 1 µL RevertAid transcriptase, the reaction was run for 10 min
at 25 ◦C, 60 min at 42 ◦C and 10 min at 70 ◦C. The cDNA was diluted to 3 ng/µL for qPCR analysis.
Additionally, total RNA was diluted to 3 ng/µL for noRT-control.
2.5. Design of Primer Sequences for qPCR
Primers were designed for use with SYBR Green in qPCR assays. The mRNA sequences of the
respective genes were downloaded from NCBI/gene website and primers were designed using the
primer-BLAST tool (NCBI, Bethesda, MD, USA). All primers were designed with a GC content from
40% to 60%, a melting temperature between 58 ◦C and 60 ◦C with an optimum at 60 ◦C and a primer
length between 18 bp and 22 bp with an optimum at 20 bp. Sequences are shown in Table S1.
2.6. Quantitative PCR (qPCR) Analysis
For analysis of relative gene expression of epithelial and fibroblast markers in PDOs and cell
lines, primers were diluted to 7.5 µM in H2O. A total amount of 9 ng cDNA or noRT-control was
loaded together with 0.5 µL fwd-primer, 0.5 µL rev-primer and 5 µL Power SYBR Green PCR Master
Mix (Thermo Scientific) in a final volume of 10 µL in triplicates in 384-well qPCR plates. Negative
controls lacking cDNA were included in the assay. The qPCR was run with the LightCycler 480
Instrument II (Roche, Basel, Switzerland) using the following program: 10 min at 95 ◦C, followed by
40 cycles denature for 15 s at 95 ◦C and annealing for 60 s at 60 ◦C. The relative expression of target
genes was normalized to β-actin expression and calculated as fold-change over all samples using the
2−∆∆Ct method.
2.7. Isolation of DNA from Organoid Cultures
For DNA isolation from the organoid cultures, matrigel domes were each resuspended with 1 mL
ice-cold 1× PBS and transferred to an Eppendorf tube. The organoids were then centrifuged at 5300 rpm
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and 4 ◦C for 5 min. The supernatant was discarded and the organoid pellet was resuspended in 500 µL
Cell Recovery Solution and incubated on ice for one hour. Organoids were then centrifuged again at
5300 rpm and 4 ◦C for 5 min and the supernatant was removed. The pellet was washed with 500 µL
ice-cold 1× PBS and centrifuged for 10 min at 5300 rpm and 4 ◦C. The supernatant was discarded and
the organoid pellet was frozen at −80 ◦C until DNA isolation. DNA was isolated with the QIAamp
DNA Micro Kit (Qiagen) using the protocol “Isolation of Genomic DNA from Tissues” according to
the manufacturer's instructions. DNA was frozen at −20 ◦C until subsequent ddPCR analyses.
2.8. Droplet Digital PCR (ddPCR)
Locked nucleic acid (LNA) probes and corresponding primer pairs for KRAS mutations were
designed using Beacon Designer v.8.20 software (Premier Biosoft, Palo Alto, CA, USA). Primers and
probes were manufactured by Integrated DNA Technologies (IDT, Inc., Coralville, IA, USA). Detailed
information on primer and probe design as well as the corresponding sequences have been published
previously [50]. Primers, probes, 2 µL/well template DNA, and nuclease-free water (Ambion) were
added to ddPCR Supermix for Probes (Bio-Rad, cat. no #186-3024). Reaction mix was set up as
recommended and droplets were generated using a QX100/200TM Droplet Generator (Bio-Rad, cat.
no. #1863002) following manufacturer’s instructions. Each sample was assayed in quadruplicates.
Following Droplet Generation, droplets were transferred into a 96-well PCR plate (Bio-Rad, cat.
no. #12001925). PCR was run on a C1000 TouchTM Thermal Cycler (Bio-Rad, cat. no. #1851197),
and samples were subsequently analyzed on a QX100/200TM Droplet Reader (Bio-Rad, cat. no. 1863003)
using QuantaSoft v1.7.4.0917 (Bio-Rad, cat.no. #1864011). PCR protocols for the corresponding KRAS
assays, the respective assay controls, and data analysis were performed as described previously [50].
2.9. Embedding Organoids for Immunohistochemistry (IHC) Analysis
For IHC analysis, organoid domes were fixed in 500 µL 4% paraformaldehyde (PFA) solution at
RT for 15 min after removal of feeding medium. PFA was removed and domes were embedded in
1 mL of 2% agarose (w/v; in water) solution. After polymerization, the embedded domes were stored in
50% ethanol (v/v) at 4 ◦C until further processing. The domes were embedded in paraffin, cut into
3 µm sections and placed on coverslips.
2.10. Immunohistochemistry Staining
For IHC staining, sections were incubated overnight at 37 ◦C, deparaffinized and boiled in a
pressure cooker in 10 mM citrate buffer (pH 6.0, supplemented with 0.05% Tween20) for 15 min.
Endogenous peroxidase activity was quenched with peroxidase-blocking-solution for 30 min, followed
by 3 × 5 min wash in TBS-T (pH 7.6, 0.05% Tween20). The background was blocked with 1% BSA/TBS
for 30 min. Primary antibodies were diluted in 1% BSA/TBS (αSMA 1:400, CK19 1:400, PDX1 1:1000,
Vimentin 1:400) and slides were incubated with the respective antibodies overnight at 4 ◦C. Slides
were washed 3 × 5 min in TBS-T and incubated with EnVision+/HRP-labeled polymer anti-rabbit or
anti-mouse for 60 min at RT. Slides were washed again 3 × 5 min in TBS-T. Stainings were visualized
by incubation with the Liquid DAB+ Substrate Chromogen System (DAKO, 1:51) for 2 min, followed
by washing in water. Counter stain was done with Mayer’s hematoxylin (1:5, v/v, in water) for 5 min,
followed by incubation in water (37 ◦C) for 10 min. The coverslips were mounted using the Rotihistokitt
II (Roth, Karlsruhe, Germany). Details of the antibodies used in this study are depicted in Table S2.
2.11. Organoid Harvest and Metabolite Extraction
Organoids were passaged as described previously and cultured for eight days until matrigel
domes were confluent for harvesting. The plates were placed on ice, the medium was removed and
the matrigel domes were disrupted in 1 mL ice-cold 0.9% NaCl solution by thoroughly pipetting up
and down and transferred into 15 mL canonical tubes. Organoids from three domes were pooled for
one analysis sample and washed thrice with 10 mL ice-cold 0.9% NaCl solution to remove the matrigel
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from the cells. The metabolism was quenched by the addition of 1.5 mL ice-cold extraction buffer
(MeOH/H2O 9:1 (v/v), 1 µg/mL ribitol, 1 µg/mL phenyl-β-d-glucopyranoside) and the suspension was
transferred into 2 mL screw-cap-tubes which had been pre-filled with 300 mg glass beads. The cells
were snap-frozen in liquid nitrogen and stored at−80 ◦C until further processing. The cell samples were
applied to a Precellys Evolution tissue homogenizer for cell lysis with the following settings: 3 × 15 s
at 6500 rpm with a 10 s break between the homogenization steps. The samples were subsequently
centrifuged at 20,000 rcf and 4 ◦C for 10 min to separate cell debris. 1200 µL of the supernatant were
dried under vacuum and analyzed by GC/MS.
2.12. Metabolite Extraction from PDO Conditioned Medium
Proteins were precipitated and metabolites extracted by cold acetonitrile:methanol as described in
Lagies et al. [51]. Vacuum dried metabolite pellets were subjected to GC/MS analysis.
2.13. GC/MS Based Metabolic Profiling
Dried metabolite pellets were subjected to untargeted gas chromatography coupled to mass
spectrometry (GC/MS) based profiling as described previously [51]. In summary, metabolites were
derivatized by methoxyamine hydrochloride in pyridine followed by silylation with N-trimethylsilyl-N-
methyl trifluoroacetamide. Samples were splitlessly injected onto an HP-5MS column (60 m × 0.25 mm
× 0.25 µm) in randomized order with regular quality control samples in between. Metabolites were
analyzed by electron ionization and annotated according to retention index and mass spectral similarity
to different libraries, including an in-house database. Features were aligned by SpectConnect
and normalized to internal standard and peak-sum. Statistical analysis was conducted with
MetaboAnalyst 4.0.
2.14. Statistical Analysis
For others than untargeted metabolomics profiling data, statistics were performed using the
GraphPad prism software. Normally distributed data were compared using an unpaired t-test. Data are
displayed as mean ± standard error of the mean. A p-value < 0.05 was considered as statistically
significant. Significances were shown with symbols (*: p <0.05, **: p < 0.01, ***: p < 0.001).
2.15. Data Avialbility
Results and statistical results of metabolic profiling are provided in supplementary data files
Tables S3 and S4 for endometabolites and exometabolites, respectively. Other data will be available
upon reasonable request.
2.16. Compliance with Ethical Standards
Informed consent was obtained for the development and usage of 3D Organoid cultures from
human pancreatic cancer tissue and approved by the local Ethics Committee of the Albert-Ludwigs-
University Freiburg, Freiburg, Germany (126/17; 28 March 2017).
3. Results
3.1. Patient and Clinical Data of Organoid Lines Used in This Study
Patient-specific data of the patient-derived organoid lines used in this study are summarized
in Table 1. The table contains information about patient sex and year of birth, additional to clinical
information about the tumor grading, the KRAS mutation, and the recurrence state of the tumor. “Early
recurrence” summarizes tumor recurrence within the first six months after curative resection, whereas
“late recurrence” indicates disease recurrence more than six months after surgery.
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Table 1. Patient and clinical data of PDO lines used in this study. The table summarizes early recurrent (ER) and late recurrent (LR) patients data including sex and
age, as well as clinical data including tumor grading, KRAS mutation and state of tumor recurrence. Patient ER-1 received three cycles FOLFIRINOX prior to resection,




















ER-1 Male 32 pT3, pN1 (3/14). L0. V0. Pn1 R1 6.5 Pancreas head G2 G12R 101, Liver (1172)
ER-2 Male 67 pT3, pN1 (7/27). L1. V0. Pn1 R1 4.5 Pancreas head G2 G12D 69, Liver (1106)
ER-3 Female 66 pT3, pN2 (5/37). L1. V1. Pn1 Narrow 5.0 Pancreas body G2 G12D 42, Liver 94
LR-1 Male 77 pT3, pN2 (6/16). L1. V0. Pn1 Narrow 5.0 Pancreas head G3 G12R 538, Lung 886
LR-2 Male 72 pT2, pN2 (4/22). L1. V0. Pn1 Narrow 3.8 Pancreas head G3 G12D 431 (431)
LR-3 Male 58 pT2, pN1 (1/19). L1. V0. Pn0 R1 3.2 Pancreas head G2 G12D 492, Liver local (543)
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3.2. Analysis of Pancreas and Fibroblast Lineage Marker Expression
In order to control for the presence of pancreatic ductal cells versus fibroblasts in organoid
cultures, the expression of lineage markers for both cell types was analyzed by qPCR (Figure 1).
Gene expression was analyzed in PDO cultures, in myofibroblast-like pancreatic stellate cells (PSC,
EP1077) and the established PDAC cell lines Capan-2, HPAF-II, MiaPaCa-2, and PANC-1 (PDAC).
Expression is shown as fold-change over all samples. Most of the organoid lines expressed the
ductal lineage markers cytokeratin 19 (KRT19) and SRY-Box transcription factor 9 (Sox9). Expression
in PDAC cell lines was lower. RNA derived from PSC was used as a negative control for these
markers. The results indicated a high content of ductal adenocarcinoma cells in the organoid cultures.
Additionally, the expression of alpha smooth muscle actin (ACTA2) and vimentin (VIM) was analyzed
as markers for mesenchymal cells and fibroblasts in the cultures. ACTA2, a marker for activated
pancreatic stellate cells and cancer-associated fibroblasts, was detected in all organoid lines at very
low levels. A high expression was found in PSC, serving as a positive control for fibroblast markers.
Additionally, vimentin expression was low in all organoid lines, except for the chronic pancreatitis and
the pseudocyst samples. Vimentin is a typical marker for mesenchymal-like cells. The high expression
of vimentin in PDAC cell lines confirmed their mesenchymal type described previously [52].
Next, we assessed the mutation allele frequencies (MAFs) of the KRAS-mutations by ddPCR.
All PDO harbored high fractions of the corresponding KRAS-mutation (Figure S1). Hence, these fractions
were starkly elevated in comparison to the primary biopsies, indicating a very pure tumor population.
Besides gene expression analysis, lineage markers were also analyzed by immunohistochemistry
staining. PDO sections were stained with antibodies against cytokeratin 19 (CK19) and pancreatic and
duodenal homeobox 1 (PDX1) as epithelial and pancreas duct lineage markers (Figure 2, left panels),
as well as with antibodies against alpha smooth muscle actin (αSMA) and vimentin as fibroblast and
mesenchymal lineage markers (Figure 2, right panels). The images are grouped according to the
clinical group used for analysis. Pancreas tissue served as control. CK19 was found at high levels
in all samples. Levels of PDX1 were much more variable with low and high expressing lines in all
groups. ER-1 (early recurrent) and LR-1 (late recurrent) displayed lower levels of PDX1 compared to
all other lines. Staining against αSMA and vimentin revealed a low level or even negative staining
in all PDOs. The findings are in line with qPCR results. In conclusion, all organoid lines contained
high amounts of epithelial and ductal cells, confirming them as a suitable system to study pancreatic
ductal adenocarcinomas in vitro. However, also fibroblast markers were found, representing either
some fibroblasts in PDO cultures or an EMT phenotype, as reported for PDAC cell lines [52].




Figure 1. Gene expression analysis of epithelial, ductal and mesenchymal markers in PDOs, PDAC
cell lines and PSCs. The expression of cytokeratin 19 (KRT19; a), SOX9 (b), alpha smooth muscle actin
(ACTA2; c) and vimentin (VIM; d) was analyzed by qPCR and normalized to -actin expression. Gene
expression was analyzed in early and late recurrent PDOs as well as in a pancreatic stellate cell line
(EP1077) and the established PDAC cell lines Capan-2, HPAF-II, MiaPaCa-2 and PANC-1. Results are
depicted in a logarithmic scale as fold change over all samples. Bar charts display mean ± standard
error of the mean (n = 3).




Figure 2. Immunohistochemistry staining of PDOs. Paraffin-embedded organoids were cut into 3 µm
sections and stained with antibodies against CK19 (first column) or PDX1 (second column) as markers
for epithelial and ductal cells as well as antibodies against αSMA (third column) or vimentin (fourth
column) as markers for fibroblasts and mesenchymal cells. Brown color represents a positive signal.
Pancreatic tissue served as control. Each panel depicts approximately 500 × 675 µm.
3.3. Metabolic Analysis of PDOs Derived from Early and Late Recurrent PDAC Patients
Following validation of the organoid cultures, untargeted metabolomics analysis was conducted
in early passage PDOs. For that, each PDO culture was measured in at least three technical replicates.
As early and late recurrent PDAC patients could clearly be assigned to different clinical entities,
we conducted a partial least square discriminant analysis (PLS-DA). Indeed, PLS-DA revealed that
there were significant global alterations within the two metabolite pools, as shown by separated
confidence intervals (see Figure 3a).
Next, we analyzed which metabolic pathways were differently regulated in early and late recurrent
PDOs. Indeed, several pathways were affected when comparing early and late recurrent PDAC patients
(see Figure 3b). Table 2 summarizes the pathway entities from Figure 3b with corresponding pathway
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impact and statistical evaluation. More than half of the most affected pathways regulated differently in




Figure 3. Metabolic profiling revealed tricarboxylic acid cycle (TCA-cycle) intermediates and anaplerotic
amino acids were increased in early recurrent PDAC. (a) Partial least square discriminant analysis of
PDOs derived from early (red) and late (green) recurrent PDAC patient unveiled global metabolic
alterations. (b) Global pathway analysis revealed different pathways affected in PDOs. Identity of the
pathways matching the cut-off values (−log(p) > 4 and pathway impact > 0.2) are depicted in table 2.
(c) Volcano plot analysis of identified metabolites. Early recurrent to late recurrent fold changes are
displayed as log2 values. Only top five altered metabolites are labeled. Each data point represents at
least three technical replicates of the different PDOs.
To further elucidate which metabolites contributed most to this separation, we conducted
a volcano-plot analysis (Figure 3c). Fumarate and malate were the most increased TCA-cycle
intermediates in PDOs derived from early recurrent PDAC patients. In parallel, glutamine, glutamate,
and aspartate were also starkly elevated in the early recurrence group. These metabolites are in line
with the identified pathways from Figure 3b and Table 2.
In addition to the PDOs themselves, the PDO-conditioned culture medium was subjected to
metabolic profiling. PLS-DA revealed again a discrimination between early and late recurrence
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(Figure 4a). The hypothesis of anaplerotic TCA-cycle activity in early recurrent PDAC could be
substantiated by volcano plot analysis (Figure 4b) with the following observations: First, culture
medium of PDOs derived from late recurrent PDAC patients had less glucose, which indicates that
they relied more on glucose as an energy source. Second, asparagine was reduced in the medium
of early recurrent PDOs, suggesting a higher import. Third, elevated secretion of α-keto carboxylic
acid, including branched-chain ketoacids (BCKAs), in the early recurrence group indicates a higher
activity of transaminases. BCATs (BCKA amino transferases) use branched chain amino acids to
produce glutamate and BCKAs and ALT (alanine amino transferase) uses alanine to form glutamate
and pyruvate. Therefore, these results are also in line with the highly increased intracellular glutamate
concentration in early recurrent PDOs.
 
α
Figure 4. Exometabolome analysis of PDAC derived PDOs. (a) PLS-DA revealed discrimination
between metabolites excreted from early recurrent PDOs (red) and late recurrent PDOs (green). (b)
Volcano plot analysis of extracellular metabolites. Early recurrent to late recurrent fold changes are
displayed as log2 values. Only top five metabolites are labeled. Each data point represents at least
three technical replicates of the different PDOs.
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Table 2. Pathway entities with quality criteria and statistics from analysis shown in Figure 3b.
Pathway Abbreviation Pathway Pathway Impact −log(p)
(a) Alanine, aspartate and glutamate metabolism 0.6234 9.4709
(b) beta-Alanine metabolism 0.39925 7.5625
(c) Pyruvate metabolism 0.32192 7.0445
(d) Histidine metabolism 0.22131 5.7457
(e) TCA cycle 0.24338 4.7773
(f) Glutamine and glutamate metabolism 0.5 4.8607
(g) Starch and sucrose metabolism 0.55921 4.4369
4. Discussion
In this study, we successfully generated and validated patient-derived organoid cultures from
PDAC patients, who went on to developed recurrence after surgical resection either within six months
(early recurrence) or later than six months (late recurrence). We demonstrated tissue identity of these
PDO cultures by both mRNA analysis and immunohistochemistry analysis of typical lineage markers.
ddPCR unraveled high MAFs of KRAS in all PDOs, further validating our cultures as cancer organoids.
To the best of our knowledge, this is the first study comparing metabolites in PDOs from these two
distinct, clinically significant PDAC subgroups. Of note, organoids of all patients were generated
from resected primary biopsies at the time of operation when further disease course was still obscure.
We could uncover higher levels of anaplerotic amino acids and TCA-cycle intermediates in the early
recurrence group. In addition, the analysis of exometabolites unveiled elevated levels of α-keto acids
and glucose together with decreased levels of asparagine in medium conditioned by early recurrent
PDOs. Dufour and colleagues showed that PDAC bears in general low expression of asparagine
synthetase and therefore is in high need for extracellular asparagine [53]. They suggested that an
asparagine-low diet could have beneficial effects for PDAC patients. As we could show diminished
levels of asparagine, we speculate that such an asparagine starvation could also delay PDAC recurrence
after surgical resection.
Higher extracellular levels of glucose in early recurrent PDAC indicate a decreased dependency
on glycolysis in comparison to late recurrent PDAC PDOs. Viale et al. have already proposed
that a PDAC sub-population could be responsible for PDAC relapse and elegantly showed an
increased reliance on the TCA-cycle within this population [54]. As a consequence, they proposed that
targeting the TCA-cycle might be a potential treatment option for PDAC therapy. Therefore, we think
that in agreement with our results (higher extracellular glucose and higher intracellular TCA-cycle
intermediates) these metabolic alterations might not only serve as a clinically applicable biomarker of
early versus late disease recurrence but also as a therapeutic target to delay recurrence after surgical
therapy. Of note, we here present a pilot study with low sample numbers and larger prospective trials
are needed to confirm our findings in a larger patient population.
The laboratory of Joshua Rabinowitz compared metabolite concentrations in pancreatic cancer
tissue with adjacent benign tissue and uncovered relatively higher levels of glutamic acid in pancreatic
malignant tissue [55]. However, the amino acids which were relatively lower were nitrogen donors.
Therefore, they speculated that increased deamination led to the opposing abundance of specific amino
acids. In another study, they showed that in almost all tissues the TCA-cycle is mainly fueled by lactate,
with the exception of the pancreas, which uses primarily glutamine/glutamate for this purpose [56].
These results are again in line with our observation of increased consumption of nitrogen donors and
increased intracellular glutamate levels in early PDAC PDOs, which can be seen as more malignant
tissue in comparison to PDOs derived from late recurrent PDAC patients.
In humans, deamination reactions are normally catalyzed by transaminases, in which an amine
group of an α-amino acid is transferred, resulting in glutamic acid and an α-keto carboxylic acid.
Not only have we detected elevated levels of glutamic acid within the early recurrent PDO-cultures,
but also have we detected several α-keto carboxylic acids in those supernatants. Therefore, it is
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reasonable that higher transaminase activities also go along with an earlier relapse of PDAC.
Confirmatory, Li et al. have proven high levels of mitochondrial branched-chain amino acid
aminotransferase (BCAT2) in human PDAC. Subsequently, they showed in a Kras-driven PDAC
mouse model that pancreas weight is significantly reduced in bcat2−/− PDAC mice [57]. Whereas
BCAT2 is elevated in PDAC, enzymes metabolizing branched chained keto acids (BCKAs), i.e.,
BCKA-dehydrogenases are simultaneously decreased [58]. This further explains the elevated levels of
BCKAs found in PDO-conditioned medium in the early recurrence group.
Taken together, common features of malignant pancreas cancer, i.e., high transaminase and
TCA-cycle activity, are even more distinctive in cancers from patients who suffer from early recurrence
after resection. Therefore, targeting these pathways might prolong survival of PDAC patients after
surgery in the future.
5. Conclusions
In this study, we generated PDOs from early and late recurrent PDAC patients and uncovered
metabolic alterations, which suggest an increased TCA-cycle activity and increased transamination
in early recurrent PDOs. These are common features in malignant transformations of pancreatic
tissue and their higher manifestation in early recurrent PDAC PDOs present a possible therapeutic
vulnerability to fight pancreatic cancer relapse in the future.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/6/1440/s1,
Figure S1: Mutation allele frequencies of KRAS, Table S1: Primer sequences used in this study, Table S2: Antibodies
used in this study, Table S3: Results of endometabolic profiling, Table S4: Results of exometabolic profiling.
Author Contributions: All authors have read and agree to the published version of the manuscript.
Conceptualization, R.M.F., B.K., and U.A.W.; Formal analysis, L.M.B. and S.L.; Investigation, L.M.B., S.L.,
R.F.U.K., and S.H.; Methodology, L.M.B., R.F.U.K., and S.H.; Resources, R.M.F.; Supervision, B.K. and U.A.W.;
Visualization, L.M.B., S.L., and S.H.; Writing—original draft, L.M.B. and S.L.; Writing—review and editing, R.M.F.,
B.K., and U.A.W.
Funding: The article processing charge was funded by the German Research Foundation (DFG) and the University
of Freiburg in the funding program Open Access Publishing. R.F.U.K. and R.M.F. were funded by the Collaborative
Research Center 850, project C09 (DFG), the German Cancer Consortium, and the Iten-Kohaut Foundation Zurich.
S.H. is a recipient of a DGHO-GMIHO thesis fellowship.
Acknowledgments: We thank Silke Hempel, Stephanie Mewes and Marie-Claire Rittmann for excellent technical
support and Olivia Sick and Julian Hipp for providing clinical data.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Muniraj, T.; Jamidar, P.A.; Aslanian, H.R. Pancreatic cancer: A comprehensive review and update. Dis. Mon.
DM 2013, 59, 368–402. [CrossRef]
2. Ilic, M.; Ilic, I. Epidemiology of pancreatic cancer. World J. Gastroenterol. 2016, 22, 9694–9705. [CrossRef]
3. Heinemann, V. Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology 2001, 60, 8–18.
[CrossRef] [PubMed]
4. Kamisawa, T.; Wood, L.D.; Itoi, T.; Takaori, K. Pancreatic cancer. Lancet 2016, 388, 73–85. [CrossRef]
5. Kleeff, J.; Korc, M.; Apte, M.; la Vecchia, C.; Johnson, C.D.; Biankin, A.V.; Neale, R.E.; Tempero, M.; Tuveson,
D.A.; Hruban, R.H.; et al. Pancreatic cancer. Nat. Rev. Dis. Prim. 2016, 2, 16022. [CrossRef] [PubMed]
6. Siegel, R.L.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA A Cancer J. Clin. 2014, 64, 9–29. [CrossRef]
7. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L. Projecting Cancer
Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United
States. Cancer Res. 2014, 74, 2913–2921. [CrossRef]
8. Neoptolemos, J.P.; Kleeff, J.; Michl, P.; Costello, E.; Greenhalf, W.; Palmer, D.H. Therapeutic developments
in pancreatic cancer: Current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 333–348.
[CrossRef]
9. SEER Cancer Statistics Review, 1975–2016. Available online: https://seer.cancer.gov/csr/1975_2016/index.html
(accessed on 22 April 2020).
Cancers 2020, 12, 1440 15 of 17
10. Couch, F.J.; Johnson, M.R.; Rabe, K.G.; Brune, K.; De Andrade, M.; Goggins, M.; Rothenmund, H.;
Gallinger, S.J.; Klein, A.; Petersen, G.M.; et al. The Prevalence of BRCA2 Mutations in Familial Pancreatic
Cancer. Cancer Epidemiol. Biomark. Prev. 2007, 16, 342–346. [CrossRef]
11. Goldstein, A.M.; Fraser, M.C.; Hussussian, C.J.; Zametkin, D.P.; Fontaine, L.S.; Organic, S.M.; Dracopoli, N.C.;
Struewing, J.; Ranade, K.; Clark, W.H.; et al. Increased Risk of Pancreatic Cancer in Melanoma-Prone
Kindreds withp16INK4Mutations. N. Engl. J. Med. 1995, 333, 970–975. [CrossRef]
12. McWilliams, R.; Petersen, G.M.; Rabe, K.G.; Holtegaard, L.M.; Lynch, P.J.; Bishop, M.D.; Highsmith, W.E.
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic
adenocarcinoma. Cancer 2009, 116, 203–209. [CrossRef] [PubMed]
13. Iodice, S.; Gandini, S.; Maisonneuve, P.; Lowenfels, A.B. Tobacco and the risk of pancreatic cancer: A review
and meta-analysis. Langenbecks Archiv für Chirurgie 2008, 393, 535–545. [CrossRef] [PubMed]
14. Hidalgo, M.; Cascinu, S.; Kleeff, J.; Labianca, R.; Löhr, J.-M.; Neoptolemos, J.P.; Real, F.X.; Van Laethem, J.-L.;
Heinemann, V. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes.
Pancreatology 2015, 15, 8–18. [CrossRef] [PubMed]
15. Oberstein, P.E.; Olive, K.P. Pancreatic cancer: Why is it so hard to treat? Ther. Adv. Gastroenterol. 2013, 6,
321–337. [CrossRef] [PubMed]
16. Partensky, C. Toward a Better Understanding of Pancreatic Ductal Adenocarcinoma. Pancreas 2013, 42,
729–739. [CrossRef]
17. Maitra, A.; Hruban, R.H. Pancreatic Cancer. Annu. Rev. Pathol. 2008, 3, 157–188. [CrossRef]
18. Collisson, E.A.; Bailey, P.; Chang, D.K.; Biankin, A.V. Molecular subtypes of pancreatic cancer. Nat. Rev.
Gastroenterol. Hepatol. 2019, 16, 207–220. [CrossRef]
19. Kamisawa, T.; Isawa, T.; Koike, M.; Tsuruta, K.; Okamoto, A. Hematogenous Metastases of Pancreatic Ductal
Carcinoma. Pancreas 1995, 11, 345–349. [CrossRef]
20. Stathis, A.; Moore, M.J. Advanced pancreatic carcinoma: Current treatment and future challenges. Nat. Rev.
Clin. Oncol. 2010, 7, 163–172. [CrossRef]
21. Gillen, S.; Schuster, T.; Büschenfelde, C.M.Z.; Friess, H.; Kleeff, J. Preoperative/Neoadjuvant Therapy in
Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Med.
2010, 7, e1000267. [CrossRef]
22. Oettle, H.; Neuhaus, P.; Hochhaus, A.; Hartmann, J.T.; Gellert, K.; Ridwelski, K.; Niedergethmann, M.;
Zülke, C.; Fahlke, J.; Arning, M.B.; et al. Adjuvant Chemotherapy With Gemcitabine and Long-term
Outcomes Among Patients With Resected Pancreatic Cancer. JAMA 2013, 310, 1473. [CrossRef] [PubMed]
23. Schnelldorfer, T.; Ware, A.; Sarr, M.G.; Smyrk, T.C.; Zhang, L.; Qin, R.; Gullerud, R.E.; Donohue, J.H.;
Nagorney, D.M.; Farnell, M.B. Long-Term Survival After Pancreatoduodenectomy for Pancreatic
Adenocarcinoma. Ann. Surg. 2008, 247, 456–462. [CrossRef] [PubMed]
24. Iovanna, J.; Mallmann, M.C.; Goncalves, A.; Turrini, O.; Dagorn, J.-C. Current Knowledge on Pancreatic
Cancer. Front. Oncol. 2012, 2. [CrossRef] [PubMed]
25. Hackert, T.; Büchler, M.W. Pancreatic Cancer: Advances in Treatment, Results and Limitations. Dig. Dis.
2013, 31, 51–56. [CrossRef] [PubMed]
26. Broeck, A.V.D.; Sergeant, G.; Ectors, N.; Van Steenbergen, W.; Aerts, R.; Topal, B. Patterns of recurrence after
curative resection of pancreatic ductal adenocarcinoma. Eur. J. Surg. Oncol. 2009, 35, 600–604. [CrossRef]
[PubMed]
27. Griffin, J.F.; Smalley, S.R.; Jewell, W.; Paradelo, J.C.; Reymond, R.D.; Hassanein, R.E.S.; Evans, R.G. Patterns
of failure after curative resection of pancreatic carcinoma. Cancer 1990, 66, 56–61. [CrossRef]
28. Moletta, L.; Serafini, S.; Valmasoni, M.; Pierobon, E.S.; Ponzoni, A.; Sperti, C. Surgery for Recurrent Pancreatic
Cancer: Is It Effective? Cancers 2019, 11, 991. [CrossRef]
29. Matsumoto, I.; Murakami, Y.; Shinzeki, M.; Asari, S.; Goto, T.; Tani, M.; Motoi, F.; Uemura, K.; Sho, M.;
Satoi, S.; et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic
ductal adenocarcinoma after surgical resection: A multi-center retrospective study. Pancreatology 2015, 15,
674–680. [CrossRef]
30. Kim, T.H.; Han, S.-S.; Park, S.-J.; Lee, W.J.; Woo, S.M.; Yoo, T.; Moon, S.H.; Kim, S.H.; Hong, E.K.; Kim, D.Y.;
et al. CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic
Cancer. Int. J. Radiat. Oncol. 2011, 81, 743–748. [CrossRef]
Cancers 2020, 12, 1440 16 of 17
31. Matsumoto, I.; Tanaka, M.; Shirakawa, S.; Shinzeki, M.; Toyama, H.; Asari, S.; Goto, T.; Yamashita, H.; Ishida, J.;
Ajiki, T.; et al. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in
Patients with Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2014, 22, 2408–2415. [CrossRef]
32. Kang, C.M.; Kim, J.Y.; Choi, G.H.; Kim, K.S.; Choi, J.S.; Lee, W.J.; Kim, B.R. The Use of Adjusted Preoperative
CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer. J. Surg. Res. 2007, 140, 31–35. [CrossRef]
[PubMed]
33. Tani, M.; Kawai, M.; Miyazawa, M.; Hirono, S.; Ina, S.; Nishioka, R.; Fujita, Y.; Uchiyama, K.; Yamaue, H.
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic
adenocarcinoma. Langenbecks Archiv für Chirurgie 2008, 394, 249–253. [CrossRef] [PubMed]
34. Takahashi, H.; Ohigashi, H.; Ishikawa, O.; Gotoh, K.; Yamada, T.; Nagata, S.; Tomita, Y.; Eguchi, H.; Doki, Y.;
Yano, M. Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern
of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable
Pancreatic Cancer. Ann. Surg. 2012, 255, 95–102. [CrossRef] [PubMed]
35. Villarroel, M.C.; RajeshKumar, N.V.; Garrido-Laguna, I.; de Jesus-Acosta, A.; Jones, S.; Maitra, A.;
Hruban, R.H.; Eshleman, J.R.; Klein, A.; Laheru, D.; et al. Personalizing cancer treatment in the age
of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic
cancer. Mol. Cancer Ther. 2010, 10, 3–8. [CrossRef]
36. Takai, E.; Yachida, S. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
World J. Gastroenterol. 2016, 22, 8480–8488. [CrossRef]
37. Zhang, X.; Shi, S.; Zhang, B.; Ni, Q.; Yu, X.; Xu, J. Circulating biomarkers for early diagnosis of pancreatic
cancer: Facts and hopes. Am. J. Cancer Res. 2018, 8, 332–353.
38. Lagies, S.; Schlimpert, M.; Braun, L.M.; Kather, M.; Plagge, J.; Erbes, T.; Wittel, U.A.; Kammerer, B. Unraveling
altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass
spectrometry. Anal. Bioanal. Chem. 2019, 411, 6319–6328. [CrossRef]
39. Moreira, L.; Bakir, B.; Chatterji, P.; Dantes, Z.; Reichert, M.; Rustgi, A.K. Pancreas 3D Organoids: Current
and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. Cell. Mol.
Gastroenterol. Hepatol. 2017, 5, 289–298. [CrossRef]
40. Gadaleta, E.; Cutts, R.J.; Kelly, G.P.; Crnogorac-Jurcevic, T.; Kocher, H.; Lemoine, N.; Chelala, C. A global
insight into a cancer transcriptional space using pancreatic data: Importance, findings, and flaws. Nucleic
Acids Res. 2011, 39, 7900–79007. [CrossRef]
41. Lagies, S.; Schlimpert, M.; Neumann, S.; Wäldin, A.; Kammerer, B.; Borner, C.; Peintner, L. Cells grown in
three-dimensional spheroids mirror in vivo metabolic response of epithelial cells. Commun. Boil. 2020, 3,
1–10. [CrossRef]
42. Kim, M.P.; Evans, U.B.; Wang, H.; Abbruzzese, J.L.; Fleming, J.B.; E Gallick, G.; Abbrusseze, J.L. Generation
of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc.
2009, 4, 1670–1680. [CrossRef] [PubMed]
43. Rubio-Viqueira, B.; Jimeno, A.; Cusatis, G.; Zhang, X.; Iacobuzio-Donahue, C.; Karikari, C.; Shi, C.;
Danenberg, K.; Danenberg, P.V.; Kuramochi, H.; et al. An In vivo Platform for Translational Drug
Development in Pancreatic Cancer. Clin. Cancer Res. 2006, 12, 4652–4661. [CrossRef] [PubMed]
44. Pérez–Mancera, P.A.; Guerra, C.; Barbacid, M.; Tuveson, D.A. What We Have Learned About Pancreatic
Cancer from Mouse Models. Gastroenterology 2012, 142, 1079–1092. [CrossRef] [PubMed]
45. Boj, S.F.; Hwang, C.-I.; Baker, L.A.; Chio, I.I.C.; Engle, D.D.; Corbo, V.; Jager, M.; Ponz-Sarvise, M.; Tiriac, H.;
Spector, M.S.; et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2014, 160, 324–338.
[CrossRef]
46. Blokzijl, F.; de Ligt, J.; Jager, M.; Sasselli, V.; Roerink, S.; Sasaki, N.; Huch, M.; Boymans, S.; Kuijk, E.W.;
Prins, P.; et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 2016, 538,
260–264. [CrossRef]
47. Huch, M.; Gehart, H.; van Boxtel, R.; Hamer, K.; Blokzijl, F.; Verstegen, M.M.; Ellis, E.; van Wenum, M.;
Fuchs, S.A.; de Ligt, J.; et al. Long-term culture of genome-stable bipotent stem cells from adult human liver.
Cell 2014, 160, 299–312. [CrossRef]
48. Broutier, L.; Andersson-Rolf, A.; Hindley, C.J.; Boj, S.F.; Clevers, H.; Koo, B.-K.; Huch, M. Culture and
establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic
manipulation. Nat. Protoc. 2016, 11, 1724–1743. [CrossRef]
Cancers 2020, 12, 1440 17 of 17
49. Baker, L.A.; Tiriac, H.; Tuveson, D.A. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma
Organoids from Resected Tumor Specimens. Adv. Struct. Saf. Stud. 2018, 97–115. [CrossRef]
50. Hussung, S.; Follo, M.; Klar, R.F.; Michalczyk, S.; Fritsch, K.; Nollmann, F.; Hipp, J.; Duyster, J.; Scherer, F.;
Von Bubnoff, N.; et al. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet
PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. J. Mol. Diagn. 2020.
[CrossRef]
51. Lagies, S.; Pichler, R.; Kaminski, M.M.; Schlimpert, M.; Walz, G.; Lienkamp, S.; Kammerer, B. Metabolic
characterization of directly reprogrammed renal tubular epithelial cells (iRECs). Sci. Rep. 2018, 8, 3878.
[CrossRef]
52. Gradiz, R.; Silva, H.; Carvalho, L.; Botelho, M.F.; Mota-Pinto, A. MIA PaCa-2, and PANC-1—Pancreas ductal
adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci. Rep. 2016, 6,
21648. [CrossRef] [PubMed]
53. Dufour, E.; Gay, F.; Aguera, K.; Scoazec, J.-Y.; Horand, F.; Lorenzi, P.L.; Godfrin, Y. Pancreatic Tumor
Sensitivity to Plasma L-Asparagine Starvation. Pancreas 2012, 41, 940–948. [CrossRef] [PubMed]
54. Viale, A.; Pettazzoni, P.; Lyssiotis, C.A.; Ying, H.; Sanchez, N.; Marchesini, M.; Carugo, A.; Green, T.; Seth, S.;
Giuliani, V.; et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Nature 2014, 514, 628–632. [CrossRef]
55. Kamphorst, J.J.; Nofal, M.; Commisso, C.; Hackett, S.R.; Lu, W.; Grabocka, E.; Heiden, M.G.V.; Miller, G.;
Drebin, J.A.; Bar-Sagi, D.; et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively
scavenge extracellular protein. Cancer Res. 2015, 75, 544–553. [CrossRef] [PubMed]
56. Hui, S.; Ghergurovich, J.M.; Morscher, R.J.; Jang, C.; Teng, X.; Lu, W.; Esparza, L.A.; Reya, T.; Zhan, L.;
Guo, J.Y.; et al. Glucose feeds the TCA cycle via circulating lactate. Nature 2017, 551, 115–118. [CrossRef]
[PubMed]
57. Li, J.-T.; Yin, M.; Wang, D.; Wang, J.; Lei, M.-Z.; Zhang, Y.; Liu, Y.; Zhang, L.; Zou, S.-W.; Hu, L.-P.; et al.
BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nature
2020, 22, 167–174. [CrossRef] [PubMed]
58. Mayers, J.; Torrence, M.E.; Danai, L.V.; Papagiannakopoulos, T.; Davidson, S.M.; Bauer, M.R.; Lau, A.N.;
Ji, B.W.; Dixit, P.D.; Hosios, A.M.; et al. Tissue of origin dictates branched-chain amino acid metabolism in
mutant Kras-driven cancers. Science 2016, 353, 1161–1165. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
